3月7日,心通医疗-B(02160)发布公告,预计截至2024年12月31日止年度净亏损将大幅减少,预计范围为3000万元至6000万元,较截至2023年12月31日止年度减少约87%至94%。这一变化主要得益于公司在中国市场的商业化进展以及海外市场销售的增长。
公告中提到,公司的VitaFlow®及VitaFlow Liberty®等产品的植入量持续增长,同时,VitaFlow Liberty®经导管主动脉瓣膜及可回收输送系统在报告期内获得CE标志,并已在海外17个国家和地区实现销售,来自海外的收入较2023年度增长一倍以上。此外,公司还通过降本控费措施提升了生产效率和运营效率,进一步推动了业务的健康可持续增长。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.